WHO Backs Regeneron COVID-19 Antibody Cocktail As It Calls For Equal Access
The World Health Organization (WHO) has supported another COVID-19 therapeutic but urged the related companies and governments to address the…
Biogen Launches High-Dose Spinraza Trial In Evrysdi Treated Patients: What You Need To Know
Biogen Inc’s (NASDAQ:BIIB) Spinraza (nusinersen), spinal muscular atrophy (SMA) drug launched in early 2017, faces new competition from Roche Holdings…
Novocure To Test Its Tumor Treating Fields With Roche’s Tecentriq In Pancreatic Cancer
Novocure Ltd (NASDAQ:NVCR) has entered into a clinical trial collaboration agreement with Roche Holdings AG (OTC:RHHBY) to develop Tumor Treating Fields (TTFields) together…
Roche Beefs Up PCR-Test Portfolio With TIB Molbiol Acquisition
Roche Holdings AG (OTC:RHHBY) has agreed to acquire TIB Molbiol Group for an undisclosed amount. The deal is expected to close in…
MacroGenics’ Cancer Drug Margenza Flops On Overall Survival Analysis
MacroGenics Inc (NASDAQ:MGNX) scored a big win with its full approval for anti-HER2 drug Margenza in December 2020 based on a…
Adaptimmune Stock Moves Higher On Cancer Deal With Genentech
Adaptimmune Therapeutics plc (NASDAQ:ADAP) has announced a collaboration and license agreement with Genentech, a unit of Roche Holdings AG (OTC:RHHBY), to develop and commercialize…
Roche’s Spark Therapeutics, NeuExcell Join Forces To Develop Huntington’s Disease Gene Therapy
Privately-held NeuExcell Therapeutics has collaborated with Spark Therapeutics to develop a treatment for Huntington’s Disease (HD). Spark Therapeutics is a part of Roche Holdings…
See Why AC Immune Stock Is Trading Higher After Data From Alzheimer’s Candidate
AC Immune SA (NASDAQ:ACIU) and its collaborating partner Genentech, part of Roche Holdings AG (OTC:RHHBY), have announced topline data from Phase 2 study evaluating…
After Bladder Cancer, Roche Pulls Breast Cancer Indication For Tecentriq In US
Following a consultation from the FDA, Roche Holdings AG (OTC:RHHBY) has decided to withdraw its immunotherapy, Tecentriq (atezolizumab), to treat a type…
Shape Therapeutics, Roche Form $3B RNA Editing Collaboration
Shape Therapeutics Inc announced a multi-target strategic collaboration and license agreement with Roche Holding AG (OTC:RHHBY) for RNA editing technology. Through this…